Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014,...
- Mechanism
- Curator reviewed
Icotinib is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) which binds reversibly to the ATP binding site of the EGFR protein, preventing completion of the signal transduction cascade. EGFR is an oncogenic receptor and patients with activating somatic mutations, such as an exon 19 deletion or exon 21 L858R mutation, within the tyrosine kinase domain display unchecked cell proliferation.
- Primary indication
- Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.Curator reviewed
- Formula / weight
- C22H21N3O4 · 391.427 g/mol (avg)
- Code names
- BPI-2009
Resolves to
QQLKULDARVNMAL-UHFFFAOYSA-NSMILESC#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Icotinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account